Cytokinetics' Myqorzo hits both primary endpoints in Phase 3 trial for non-obstructive hypertrophic cardiomyopathy
Cytokinetics announced that its drug Myqorzo achieved the dual efficacy targets in the Phase 3 ACACIA trial, which evaluated patients with non-obstructive hypertrophic cardiomyopathy (HCM), an inherited form of heart disease.
The trial showed statistically significant improvements in heart-failure symptoms and cardiovascular fitness compared with placebo, meeting both primary endpoints set for the study.
Myqorzo is already marketed for the obstructive form of HCM, and the positive results could allow the company to seek regulatory approval for the non-obstructive indication, potentially expanding its market.
If cleared by regulators, the broader label could boost sales and strengthen Cytokinetics' position in the HCM therapeutic area.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Cytokinetics drug Myqorzo meets twin efficacy goals in study of genetic heart disease”
read at STAT ↗
comments(0)
5-min edit window · permanent after that